Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Prognostic factors in malignant melanoma

M Kashani-Sabet1, S P Leong, R Sagebiel

  • 1Department of Dermatology, University of California, San Francisco, Mount Zion Medical Center, San Francisco, California 94143, USA.

Surgical Oncology Clinics of North America
|July 1, 1997
PubMed
Summary

Melanoma exhibits diverse clinical and biologic behaviors. Prognostic factors include clinical, histologic, and metastatic characteristics, with potential future integration of molecular determinants for improved treatment strategies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Oncolymphology: Immune Interactions and Cancer.

Lymphology·2023
Same author

Immunotherapy for cancer.

Surgical technology international·2015
Same author

MicroRNA-mediated regulation of melanoma.

The British journal of dermatology·2014
Same author

Molecular markers in melanoma.

The British journal of dermatology·2013
Same author

Growth inhibition efficacy of an adenovirus expressing dual therapeutic genes, wild-type p53, and anti-erbB2 ribozyme, against human bladder cancer cells.

Cancer gene therapy·2005
Same author

Hammerhead ribozymes as therapeutic agents for bladder cancer.

Molecular urology·2002

Area of Science:

  • Oncology
  • Dermatology
  • Pathology

Background:

  • Melanoma presents a heterogeneous clinical spectrum and biologic behavior.
  • Prognostic assessment relies on clinical factors like sex, location, and age.
  • Histologic factors such as tumor type, thickness, and mitotic index are crucial for primary tumors.

Purpose of the Study:

  • To review the diverse prognostic factors influencing melanoma progression.
  • To highlight the role of clinical and histologic features in determining surgical treatment.
  • To explore the potential of cytogenetic and molecular determinants in refining melanoma prognosis.

Main Methods:

  • Review of clinical factors (sex, location, age).
  • Analysis of histologic prognostic factors (tumor type, thickness, mitotic index).

Related Experiment Videos

  • Evaluation of metastatic melanoma prognostic factors (lymph node status, extracapsular extension).

    • Main Results:

    • Clinical factors like sex, age, and location influence melanoma behavior.
    • Histologic features including tumor thickness and mitotic rate are key prognostic indicators.
    • For metastatic melanoma, lymph node status and extracapsular extension are significant prognostic factors.

    Conclusions:

    • Current surgical treatment decisions are guided by established clinical and histologic factors.
    • Cytogenetic and molecular markers show promise for enhancing melanoma prognostic accuracy.
    • Further research into molecular determinants is needed to solidify their role in melanoma management.